Antibody Dermatology Licensing Sales 
pharmaphorum
JUNE 2, 2021
The deal gives Amgen rights to the KHK4083 antibody in all countries except Kyowa’s home market of Japan, and is back-loaded with potential milestone payments worth another $850 million plus royalties on sales. Kyowa will co-promote the drug in the US if approved, with opt-in rights in some other countries as well.
The Pharma Data
AUGUST 3, 2021
Product sales increased 3% globally, driven by double digit volume growth across a number of our products including Prolia ® (denosumab), Repatha ® (evolocumab) and our biosimilar products MVASI ® (bevacizumab-awwb) and KANJINTI ® (trastuzumab-anns). Product Sales Performance. Key results include: Total revenues increased 5% to $6.5
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
APRIL 26, 2021
Merck licensed sonelokimab (M1095) from Ablynx in 2013, and four years later formed a partnership with Avillion to carry out phase 2 and 3 testing of the drug. The drug is a nanobody, a molecule around one-tenth the size of a regular antibody derived from camelid species such as the llama. billion in sales last year.
pharmaphorum
MAY 25, 2022
But while the company is adamant sales will pick up quickly, analysts have predicted a more challenging start for the new product. Tapinarof was GSK’s lead drug in immuno-inflammation R&D back in 2018 before it was licensed by Dermavant in a £250 million ($330 million) deal. Image by Anastasia Gepp from Pixabay.
pharmaphorum
MAY 4, 2021
There’s a new biotech on the scene after MoonLake Immunotherapeutics launched on a mission to develop sonelokimab, a potential inflammatory diseases drug in-licensed from Germany’s Merck KGaA. MoonLake has swiftly in-licensed the drug discovered by Sanofi’s Ablynx unit, with plans to develop the drug targeting IL-17A and F.
The Pharma Data
AUGUST 1, 2021
Saphnelo is a first-in-class type I interferon receptor antibody and the only new medicine in over a decade for patients with systemic lupus erythematosus . Financial considerations AstraZeneca acquired global rights to Saphnelo through an exclusive license and collaboration agreement with Medarex, Inc.
The Pharma Data
NOVEMBER 8, 2020
9, 2020 /PRNewswire/ — Solid 9M business performance despite COVID-19 and generic Aczone challenges: Net Sales €613.8 Ilumetri ® sales grew +125% year-on-year and Seysara ® showed Net Sales performance improvement quarter-on-quarter following clinically relevant FDA label improvement. BARCELONA, Spain , Nov.
Expert insights. Personalized for you.
52 
Let's personalize your content